These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19475781)

  • 1. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.
    Pimenta E; Oparil S
    Vasc Health Risk Manag; 2009; 5(1):453-63. PubMed ID: 19475781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.
    Rashikh A; Ahmad SJ; Pillai KK; Najmi AK
    J Pharm Pharmacol; 2012 Apr; 64(4):470-81. PubMed ID: 22420653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a future for direct renin inhibitors?
    Chaudhary K; Nistala R; Whaley-Connell A
    Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.
    Sureshkumar KK
    Vasc Health Risk Manag; 2008; 4(6):1205-20. PubMed ID: 19337534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.
    Angeli F; Reboldi G; Mazzotta G; Poltronieri C; Garofoli M; Ramundo E; Biadetti A; Verdecchia P
    Curr Drug Saf; 2012 Feb; 7(1):76-85. PubMed ID: 22663961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.
    Pimenta E; Oparil S
    Ther Clin Risk Manag; 2009 Jun; 5(3):459-64. PubMed ID: 19707255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct renin inhibition: focus on aliskiren.
    Pool JL
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):21-33. PubMed ID: 17970614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren: the first direct renin inhibitor available for clinical use.
    Morganti A; Lonati C
    J Nephrol; 2011; 24(5):541-9. PubMed ID: 21786226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New class of agents for treatment of hypertension: focus on direct renin inhibition.
    Fogari R; Zoppi A
    Vasc Health Risk Manag; 2010 Oct; 6():869-82. PubMed ID: 20957132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct renin inhibition: extricating facts from façades.
    Juncos L
    Ther Adv Cardiovasc Dis; 2013 Jun; 7(3):153-67. PubMed ID: 23487045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
    Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
    Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
    Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
    Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.
    Verdecchia P; Angeli F; Mazzotta G; Gentile G; Reboldi G
    Vasc Health Risk Manag; 2008; 4(5):971-81. PubMed ID: 19183745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.
    Volpe M; Pontremoli R; Borghi C
    High Blood Press Cardiovasc Prev; 2011 Sep; 18(3):93-105. PubMed ID: 21950781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.